T2 Biosystems (TTOO)
NASDAQ:TTOO

T2 Biosystems (TTOO) Stock Price & Analysis

1,901 Followers

TTOO Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$1.05 - $29.27
Previous Close$1.67
Volume87.25K
Average Volume (3M)159.61K
Market CapN/A
Enterprise ValueN/A
Total Cash (Recent Filing)$20.37M
Total Debt (Recent Filing)$59.05M
Price to Earnings (P/E)-0.1
Beta-0.85
Next EarningsMar 01, 2023
Next Dividend Ex-DateN/A
Dividend YieldN/A
EPS (TTM)-16.56
Shares Outstanding7,319,105
R-Squared0.00110
Standard Deviation0.32
10 Day Avg. Volume133,347
30 Day Avg. Volume159,613
Price to Book (P/B)-0.41
Price to Sales (P/S)0.79
Price to Cash Flow (P/CF)N/A
P/FCF Ratio-0.30
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Price Target Upside-3.23% Downside
Rating ConsensusHold
Alpha-0.03
Number of Analyst Covering3


Financials

Annual

Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.

---

TTOO FAQ

What was T2 Biosystems’s price range in the past 12 months?
T2 Biosystems lowest stock price was $1.05 and its highest was $29.27 in the past 12 months.
    What is T2 Biosystems’s market cap?
    Currently, no data Available
    When is T2 Biosystems’s upcoming earnings report date?
    T2 Biosystems’s upcoming earnings report date is Mar 01, 2023 which is in 30 days.
      How were T2 Biosystems’s earnings last quarter?
      T2 Biosystems released its earnings results on Nov 10, 2022. The company reported -$2.95 earnings per share for the quarter, missing the consensus estimate of -$2.113 by -$0.837.
        Is T2 Biosystems overvalued?
        According to Wall Street analysts T2 Biosystems’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does T2 Biosystems pay dividends?
          T2 Biosystems does not currently pay dividends.
          What is T2 Biosystems’s EPS estimate?
          T2 Biosystems’s EPS estimate is -$2.33.
            How many shares outstanding does T2 Biosystems have?
            T2 Biosystems has 7,319,105 shares outstanding.
              What happened to T2 Biosystems’s price movement after its last earnings report?
              T2 Biosystems reported an EPS of -$2.95 in its last earnings report, missing expectations of -$2.113. Following the earnings report the stock price went up 2.703%.
                Which hedge fund is a major shareholder of T2 Biosystems?
                Among the largest hedge funds holding T2 Biosystems’s share is Hussman Strategic Advisors Inc. It holds T2 Biosystems’s shares valued at N/A.

                  ---

                  T2 Biosystems Stock Smart Score

                  N/A
                  Not Ranked
                  1
                  2
                  3
                  4
                  5
                  6
                  7
                  8
                  9
                  10

                  Technicals

                  SMA
                  Negative
                  20 days / 200 days
                  Momentum
                  -91.33%
                  12-Months-Change

                  Fundamentals

                  Return on Equity
                  Trailing 12-Months
                  Asset Growth
                  -37.24%
                  Trailing 12-Months
                  This stock does not have enough of the key information we need to rate it accurately. Smart Score is calculated for stocks traded in Nasdaq, NYSE, TSE and LSE with a market cap above $30M and average 3 months trading volume above $30K.
                  Learn more about TipRanks Smart Score

                  Company Description

                  T2 Biosystems

                  T2 Biosystems, Inc. engages in the development of proprietary technology platform. It offers the T2 Magnetic Resonance technology which enables rapid detection of pathogens, biomarkers and other abnormalities in a variety of unpurified patient sample types. It products include T2Bacteria Panel, T2Candida Panel, T2Dx Instrument, AND T2MR Technology. The company was founded by Michael J. Cima, Robert S. Langer Jr., Tyler Jacks, Lee Josephson, W. David Lee, and Ralph Weissleder on April 27, 2006 and is headquartered in Lexington, MA.

                  ---

                  Forecast EPS vs Actual EPS


                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  Biocept
                  GlobeStar Therapeutics
                  Aileron Therapeutics
                  Cyclo Therapeutics
                  Organovo Holdings

                  Popular Stocks

                  ---
                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis